GoAI
Get started
TransThera Sciences (Nanjing). Inc. logo

TransThera Sciences (Nanjing). Inc.

2617.HK

HKSEHealthcareBiotechnology

Open in GoAI

Latest quote

HK$10.00

−HK$0.31 · -3.01%

Aug 24, 11:59 AM HKT

2617.HK company overview

Regular session · HKT · Market data may be delayed.

Company profile

Company website

TransThera Sciences (Nanjing), Inc., clinical stage biopharmaceutical company, discovers, develops, and commercializes small molecule therapies for oncology, inflammatory, and cardiometabolic diseases. The company provides Tinengotinib (TT-00420), a MTK inhibitor that is in clinical stage for the treatment of recurrent or refractory drug-resistant solid tumors. It also develops TT-00973, a kinase inhibitor for treating various cancers; TT-01488, a BTK inhibitor for the treatment of B-cell lymphoma; TT-01688, an oral S1P1 modulator for treating various inflammatory diseases; TT-00920, an oral PDE9 inhibitor used for treating central nervous system diseases; TT-01025, an oral irreversible VAP-1 inhibitor designed for the treatment of NASH; and TT-02332, a NLRP3 inhibitor for metabolic and inflammatory diseases. The company has a collaboration with Neurocrine Biosciences, Inc. to develop NLRP3 inhibitors for multiple disease. TransThera Sciences (Nanjing), Inc. was formerly known as Nanjing TransThera Biosciences Co. Ltd. and changed its name to TransThera Sciences (Nanjing), Inc. in July 2021. The company was incorporated in 2014 and is headquartered in Nanjing, China.

Industry
Biotechnology
Sector
Healthcare
Headquarters
CN
CEO
Yong Qian Wu
Listed since
Jun 23, 2025
Employees
123

Market position

Day range

Current HK$10.00

52-week range

Current HK$10.00

Open
HK$10.38
Previous close
HK$10.31
Volume
1.81M
0.2× average
Average volume
8.89M
Average daily volume
Market cap
3.97B HKD
Beta
3.27
Market reference 1
50-day average
HK$13.3606
-25.15% below average
200-day average
HK$75.6417
-86.78% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
39.8B CNY
P/E (TTM)
-8.4×
P/B (TTM)
8.17×
P/S (TTM)
0×
EV / EBITDA
-136.86×
Earnings yield
-0.74%
Free cash flow yield
-0.63%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
0.00%
Operating margin
0.00%
Net margin
0.00%
Return on equity
-71.08%
Return on assets
-54.22%
Return on invested capital
-71.81%

Financial health

Debt / equity
0×
Current ratio
3.87×
Altman Z-score
12.52
Piotroski F-score
1 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends22708731%-68125754%-158960239%-249794724%Gross margin, FY2022: 100.00%Gross margin, FY2023: 109.94%Operating margin, FY2020: -71.01%Operating margin, FY2022: -227086102.37%Operating margin, FY2023: -32436.64%Net margin, FY2020: -130.69%Net margin, FY2022: -183179430.48%Net margin, FY2023: -29119.32%FY2020FY2022FY2023FY2024FY2025
Gross margin FY2022 100.00%. Gross margin FY2023 109.94%. Operating margin FY2020 -71.01%. Operating margin FY2022 -227086102.37%. Operating margin FY2023 -32436.64%. Net margin FY2020 -130.69%. Net margin FY2022 -183179430.48%. Net margin FY2023 -29119.32%.

Income trends

Revenue

1.18M CNY+841198.50%

Operating income

−300.18M CNY-4.71%

Net income

−295.96M CNY-7.78%
Income trends across reported periods106.27M CNY−71.76M CNY−249.8M CNY−427.84M CNYRevenue, FY2020: 61.76M CNYRevenue, FY2022: 140.47 CNYRevenue, FY2023: 1.18M CNYOperating income, FY2020: −43.86M CNYOperating income, FY2022: −318.99M CNYOperating income, FY2023: −383.33M CNYOperating income, FY2024: −286.68M CNYOperating income, FY2025: −300.18M CNYNet income, FY2020: −80.72M CNYNet income, FY2022: −257.31M CNYNet income, FY2023: −344.12M CNYNet income, FY2024: −274.61M CNYNet income, FY2025: −295.96M CNYFY2020FY2022FY2023FY2024FY2025
Revenue FY2020 61.76M CNY. Revenue FY2022 140.47 CNY. Revenue FY2023 1.18M CNY. Operating income FY2020 −43.86M CNY. Operating income FY2022 −318.99M CNY. Operating income FY2023 −383.33M CNY. Operating income FY2024 −286.68M CNY. Operating income FY2025 −300.18M CNY. Net income FY2020 −80.72M CNY. Net income FY2022 −257.31M CNY. Net income FY2023 −344.12M CNY. Net income FY2024 −274.61M CNY. Net income FY2025 −295.96M CNY.
Metric (CNY)FY2025FY2024FY2023FY2022FY2020
Revenue——1.18M CNY140.47 CNY61.76M CNY
Gross profit——1.3M CNY140.47 CNY—
Research and development246.76M CNY244M CNY379.05K CNY297.32K CNY76.54M CNY
Selling, general, and administrative54.78M CNY47.74M CNY43.15K CNY56.56K CNY24.5M CNY
Operating expenses300.18M CNY286.68M CNY422.12M CNY353.89K CNY101.03M CNY
Interest income4.91M CNY2.17M CNY12.19M CNY6.14M CNY589.02K CNY
Interest expense121K CNY201K CNY248.52K CNY184.85K CNY37.8M CNY
Depreciation and amortization5.03M CNY6.44M CNY4.02M CNY6.87K CNY4.59M CNY
Operating income−300.18M CNY−286.68M CNY−383.33M CNY−318.99M CNY−43.86M CNY
Net income−295.96M CNY−274.61M CNY−344.12M CNY−257.31M CNY−80.72M CNY

Company facts updated Aug 24, 2026.

2617.HK peers

WuXi AppTec Co., Ltd. logo

2359.HK

WuXi AppTec Co., Ltd.

HK$197.4

-4.08%

Jiangsu Hengrui Pharmaceuticals Co.,Ltd logo

1276.HK

Jiangsu Hengrui Pharmaceuticals Co.,Ltd

HK$46.30

-3.94%

BeOne Medicines AG logo

6160.HK

BeOne Medicines AG

HK$221.8

-2.72%

WuXi Biologics (Cayman) Inc. logo

2269.HK

WuXi Biologics (Cayman) Inc.

HK$48.54

-4.82%

Hansoh Pharmaceutical Group Company Limited logo

3692.HK

Hansoh Pharmaceutical Group Company Limited

HK$31.14

-5.86%

Innovent Biologics, Inc. logo

1801.HK

Innovent Biologics, Inc.

HK$100.5

-1.86%

ETFs holding 2617.HK

Funds reporting this stock among their holdings, ordered by reported position size.

State Street SPDR S&P China ETF logoState Street SPDR S&P China ETFGXC
Market value
1.32K
Weight
0.00%
AUM
474.65M USD
Expense ratio
0.59%
Price / 1D
$91.50+0.51%

Continue in GoAI

Research 2617.HK

research.disclaimer